Novartis Acquires ABO2203 Rights from Abogen in $7.8 Billion Deal

Key Facts

1Novartis acquired global rights to ABO2203 from Abogen Biosciences as part of a deal valued at $7.8 billion.

Novartis acquired global rights to ABO2203 from Abogen Biosciences as part of a deal valued at $7.8 billion. Zacks reported that the acquisition focuses on strengthening the company's RNA therapeutics pipeline, specifically targeting B-cell-mediated autoimmune diseases.

NVSEF closed at $134.20 on October 2, 2026, with the stock reaching a day high of $137.40 and a low of $134.20 during that session. The strategic expansion aims to bolster the position of Novartis in the RNA market and provide a new therapeutic approach for autoimmune conditions.